Skip to main content
Springer logoLink to Springer
. 2017 Jul 7;31(7):603. doi: 10.1007/s40263-017-0457-5

Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

Peter Joseph Jongen 1,2,
PMCID: PMC6828088  PMID: 28688015

Erratum to: CNS Drugs DOI 10.1007/s40263-017-0444-x

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 June 2017. A number of errors were subsequently identified in the article, and the following corrections should be noted:

Page 2, column 1, line 8: The text, which previously read:

" … INFβ-1b, pegylated INFβ-1a …" should read:

“… IFNβ-1b, pegylated IFNβ-1a …”

Page 6, Table 2, ‘Outcome’ column, line 1: The text, which previously read:

“… LMSQOL score …” should read:

“… LMSQoL score …”

Page 9, column 1, line 3: The text, which previously read:

" … INFβ-1a …” should read:

“… IFNβ-1a …”

Page 11, column 2, line 11: The text, which previously read:

“ … INFβ …” should read:

“… IFNβ …”

Page 11, column 2, line 20: The text, which previously read:

“ … INFβ-1a …” should read:

“… IFNβ-1a …”

Footnotes

The online version of the original article can be found under doi:10.1007/s40263-017-0444-x.


Articles from CNS Drugs are provided here courtesy of Springer

RESOURCES